Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences

Investors can watch Opus Genetics’ OPGx-BEST1 Cohort 1 topline update live Sept. 9, with the full dataset and visual-function analyses to follow at major ophthalmology meetings.

Rhea-AI Summary

Opus Genetics (IRD) will present topline data from Cohort 1 of its Phase 1/2 OPGx-BEST1 gene therapy study during an investor conference call and webcast on Wednesday, September 9, 2026, at 8:00 a.m. ET.

The company will later share the full clinical dataset and additional analyses on visual function at multiple ophthalmology meetings, including Euretina Innovation Spotlight on September 30, 2026, Euretina 2026 on October 4, 2026, Retina in Rio on October 14, 2026, and a FLORetina presentation. These sessions will cover initial clinical results, structure-function correlations in BEST1-related retinopathy, and related gene augmentation findings in inherited retinal diseases.

Argus Sep 2 session 59 alerts

+16.71% close to close 8.6x rel. volume Open Argus

Details

News Market Reaction – IRD

+12.7% Peak in 6 hr 9 min

$375.21M Mkt Cap at Peak Alert

On Sep 2, the day this news came out, IRD closed 16.71% above the previous close. Argus tracked a peak move of +12.7% during that session. Our momentum scanner recorded 59 alerts for this stock that day. Relative volume reached 8.6x the daily average during tracking.

Data tracked by StockTitan Argus for the Sep 2 session.

Key Figures

Study Phase: Phase 1/2 Investor Webcast Date: September 9, 2026 Investor Webcast Time: 8:00 a.m. ET +4 more

Study Phase

Phase 1/2

OPGx-BEST1 Cohort 1

Investor Webcast Date

September 9, 2026

Topline Cohort 1 data presentation

Investor Webcast Time

8:00 a.m. ET

September 9, 2026

Euretina Innovation Spotlight

September 30, 2026

Clinical development update

Euretina 2026

October 4, 2026

Initial Cohort 1 results presentation

Retina in Rio

October 14, 2026

OPGx-BEST1 study presentation

Results Timepoint

3M

OPGx-BEST1 Cohort 1 results at FLORetina

Previous Clinical trial Reports

5 past events · Latest: Aug 03

Same Type 5 events

1. Aug 03

   Phase 3 enrollment

   24h Move

   -1.9%

   Enrollment completed in the registrational OPGx-LCA5 Phase 3 trial.

2. Jul 06

   Phase 3 FDA alignment

   24h Move

   -3.8%

   FDA alignment was reached on the OPGx-LCA5 registrational trial design.

3. May 07

   Cohort 1 enrollment

   24h Move

   +1.9%

   Enrollment was completed in Cohort 1 of the OPGx-BEST1 study.

4. May 04

   RDEP acceptance

   24h Move

   -0.4%

   OPGx-LCA5 entered the FDA Rare Disease Evidence Principles program.

5. Feb 27

   Initial clinical data

   24h Move

   +15.9%

   Initial OPGx-BEST1 data reported safety findings and efficacy signals.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

phase 1/2, gene therapy, microperimetry, gene augmentation

4 terms

phase 1/2 medical

"topline clinical data from Cohort 1 of its Phase 1/2 study"

Phase 1/2 is a combined early-stage clinical trial that first tests a new drug or treatment for safety and the right dose, then quickly expands to check if it shows any signs of working in patients. For investors, results from a Phase 1/2 study offer an early read on both risk and potential reward—like a prototype test that both confirms a product won’t harm users and suggests whether it could sell—helping guide valuation and development decisions.

gene therapy medical

"developing gene therapies to restore vision and prevent blindness"

Gene therapy is a medical technique that involves altering or replacing faulty genes in a person's cells to treat or prevent disease. It is considered a promising area of innovation because it has the potential to provide long-term or even permanent solutions to genetic conditions. For investors, advancements in gene therapy can signal opportunities in biotech companies and emerging treatments with significant growth potential.

microperimetry medical

"EZ-RPE Thickness and MAIA Microperimetry in BEST1-Related Retinopathy"

Microperimetry is a clinical eye test that maps how well specific spots on the retina detect light while tracking their exact location on an image of the back of the eye. For investors, it matters because it provides precise, location-specific evidence of vision improvement or decline in drug and device trials, affecting regulatory decisions, market potential and reimbursement—think of it as a high-resolution measuring stick for retinal function.

gene augmentation technical

"Near Normalization of Cone Sensitivity using Gene Augmentation"

Gene augmentation is a type of gene therapy that delivers working copies of a missing or faulty gene into a patient’s cells so those cells can produce a needed protein. Investors care because it is a distinct therapeutic approach with its own clinical development path, manufacturing needs, regulatory hurdles, and potential market impact—similar to replacing a broken part in a machine to restore normal function.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Topline data from Phase 1/2 Cohort 1 of OPGx-BEST1 gene therapy program to be presented during investor conference call and webcast on September 9 at 8:00 a.m. ET

Full clinical dataset and additional analyses evaluating key measures of visual function to be presented at upcoming medical meetings

RESEARCH TRIANGLE PARK, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (“Opus” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced plans to present topline clinical data from Cohort 1 of its Phase 1/2 study of OPGx-BEST1 during an investor conference call and webcast on Wednesday, September 9, 2026, at 8:00 a.m. ET.

The Company also plans to present the full clinical dataset and additional analyses from the OPGx-BEST1 program at several upcoming medical conferences.

Investor Conference Call and Webcast

Opus Genetics will host an investor conference call and webcast on Wednesday, September 9, 2026, at 8:00 a.m. ET to present topline data from Cohort 1 of the Phase 1/2 clinical study of OPGx-BEST1.

Date: Wednesday, September 9, 2026
Time: 8:00 a.m. ET
Webcast: Opus Genetics Investor Events

A live webcast and accompanying presentation will be available in the Investors section of the Company’s website. A replay will be available following the event.

Upcoming Conference Presentations

Euretina Innovation Spotlight (EIS)

Date: Wednesday, September 30, 2026

Time: 14:20-14:56 CEST

Presenter: Ben Yerxa

Title: Advancing the Future of IRDs: Opus Genetics Clinical Development Update

Euretina 2026

Date: Sunday, October 4, 2026

Time: 13:15-13:21 CEST 

Presenter: Mark Pennesi, M.D., Ph.D., Professor of Ophthalmology, School of Medicine, Casey Eye Institute, School of Medicine

Title: Initial Results from Cohort 1 of a Phase 1b/2a Clinical Study of OPGx-BEST1 Gene Therapy for the Treatment of BVMD and ARB Due to BEST1 Mutations

Retina in Rio 

Date: Wednesday, October 14, 2026

Title: Structure-Function Correlation of EZ-RPE Thickness and MAIA Microperimetry in BEST1-Related Retinopathy: Results from the Phase 1/2 BIRD-1 Study of OPGx-BEST1 Gene Therapy

Presenter: George Magrath, M.D, CEO, Opus Genetics

Title: Near Normalization of Cone Sensitivity using Gene Augmentation in Children with LCA5

Presenter: Rodrigo Jorge, M.D., Ph.D., Head of Ophthalmology Department at University of São Paulo

FLORetina Presentation

Title: Phase 1/2 Cohort 1 3M Results of OPGx-BEST1 Gene Therapy in Patients with BVMD and ARB Due to BEST1 Mutations

Presenter: Aaron Nagiel, M.D., Ph.D.

About OPGx-BEST1

OPGx-BEST1 is an investigational gene therapy designed to address the underlying genetic cause of BEST1-related inherited retinal diseases, including BVMD and ARB. OPGx-BEST1 uses an AAV vector to deliver a functional copy of the BEST1 gene to retinal pigment epithelial cells. The ongoing BIRD-1 study is an adaptive, open-label Phase 1/2 clinical trial evaluating the safety and efficacy of single-eye subretinal administration of OPGx-BEST1 in adults with BVMD or ARB.

About Opus Genetics

Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RDH12, MERTK, RHO, CNGB1 and NMNAT1. The Company is based in Research Triangle Park, NC. For more information, visit www.opusgtx.com.

Contacts

Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
ir@opusgtx.com

Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Opus Genetics (IRD) presenting OPGx-BEST1 Cohort 1 topline data to investors?

Opus Genetics will present topline data from Cohort 1 of its Phase 1/2 OPGx-BEST1 study during an investor conference call and webcast on Wednesday, September 9, 2026, at 8:00 a.m. ET.

How can investors access the Opus Genetics (IRD) OPGx-BEST1 topline data webcast?

A live webcast and accompanying presentation for the OPGx-BEST1 topline data will be available in the Investors section of the Opus Genetics website. A replay will be available following the event.

What clinical program is Opus Genetics (IRD) highlighting in the September 9, 2026 webcast?

The webcast will highlight topline results from Cohort 1 of the Phase 1/2 clinical study of OPGx-BEST1, a gene therapy program for BEST1-related inherited retinal diseases.

At which ophthalmology conferences will Opus Genetics (IRD) present OPGx-BEST1 clinical data?

Opus Genetics plans to present OPGx-BEST1 data at Euretina Innovation Spotlight on September 30, 2026, Euretina 2026 on October 4, 2026, Retina in Rio on October 14, 2026, and a FLORetina session.

What will be presented about OPGx-BEST1 at Euretina 2026 for Opus Genetics (IRD)?

At Euretina 2026 on October 4, 2026, Mark Pennesi, M.D., Ph.D., will present “Initial Results from Cohort 1 of a Phase 1b/2a Clinical Study of OPGx-BEST1 Gene Therapy for the Treatment of BVMD and ARB Due to BEST1 Mutations.”

What OPGx-BEST1 study results will be discussed at Retina in Rio for Opus Genetics (IRD)?

At Retina in Rio on October 14, 2026, a presentation titled “Structure-Function Correlation of EZ-RPE Thickness and MAIA Microperimetry in BEST1-Related Retinopathy: Results from the Phase 1/2 BIRD-1 Study of OPGx-BEST1 Gene Therapy” will be delivered by George Magrath, M.D.

What FLORetina presentation is planned on OPGx-BEST1 Cohort 1 for Opus Genetics (IRD)?

At FLORetina, Aaron Nagiel, M.D., Ph.D., will present “Phase 1/2 Cohort 1 3M Results of OPGx-BEST1 Gene Therapy in Patients with BVMD and ARB Due to BEST1 Mutations,” covering three-month outcomes from the first cohort.